JP2018529759A - 治療用コネキシン４５阻害剤 - Google Patents

治療用コネキシン４５阻害剤 Download PDF

Info

Publication number
JP2018529759A
JP2018529759A JP2018526974A JP2018526974A JP2018529759A JP 2018529759 A JP2018529759 A JP 2018529759A JP 2018526974 A JP2018526974 A JP 2018526974A JP 2018526974 A JP2018526974 A JP 2018526974A JP 2018529759 A JP2018529759 A JP 2018529759A
Authority
JP
Japan
Prior art keywords
sequence
vector
ventricular
inhibitor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529759A5 (enExample
Inventor
キザナ，エディー
ファーミー，ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Western Sydney Local Health District
Original Assignee
Western Sydney Local Health District
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903282A external-priority patent/AU2015903282A0/en
Application filed by Western Sydney Local Health District filed Critical Western Sydney Local Health District
Publication of JP2018529759A publication Critical patent/JP2018529759A/ja
Publication of JP2018529759A5 publication Critical patent/JP2018529759A5/ja
Priority to JP2021104925A priority Critical patent/JP7668686B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018526974A 2015-08-14 2016-08-12 治療用コネキシン４５阻害剤 Pending JP2018529759A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021104925A JP7668686B2 (ja) 2015-08-14 2021-06-24 治療用コネキシン４５阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903282A AU2015903282A0 (en) 2015-08-14 Connexin 45 Inhibition for Therapy
AU2015903282 2015-08-14
PCT/AU2016/050740 WO2017027910A1 (en) 2015-08-14 2016-08-12 Connexin 45 inhibition for therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021104925A Division JP7668686B2 (ja) 2015-08-14 2021-06-24 治療用コネキシン４５阻害剤

Publications (2)

Publication Number Publication Date
JP2018529759A true JP2018529759A (ja) 2018-10-11
JP2018529759A5 JP2018529759A5 (enExample) 2020-12-24

Family

ID=58050389

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018526974A Pending JP2018529759A (ja) 2015-08-14 2016-08-12 治療用コネキシン４５阻害剤
JP2021104925A Active JP7668686B2 (ja) 2015-08-14 2021-06-24 治療用コネキシン４５阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021104925A Active JP7668686B2 (ja) 2015-08-14 2021-06-24 治療用コネキシン４５阻害剤

Country Status (6)

Country Link
US (1) US10709726B2 (enExample)
EP (2) EP3334746B1 (enExample)
JP (2) JP2018529759A (enExample)
AU (2) AU2016309948B2 (enExample)
CA (1) CA3033909A1 (enExample)
WO (1) WO2017027910A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200061210A1 (en) * 2018-08-27 2020-02-27 BioViva USA, Inc. Novel method for gene therapy using intranasal administration of genetically modified viral vectors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528678A (ja) * 2005-02-03 2008-07-31 コーダ セラピューティクス リミテッド 抗コネキシン化合物およびそれらの使用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA962806A (en) 1970-06-04 1975-02-18 Ontario Research Foundation Surgical prosthetic device
US4281669A (en) 1975-05-09 1981-08-04 Macgregor David C Pacemaker electrode with porous system
US4101984A (en) 1975-05-09 1978-07-25 Macgregor David C Cardiovascular prosthetic devices and implants with porous systems
IT1196836B (it) 1986-12-12 1988-11-25 Sorin Biomedica Spa Protesi in materiale polimerico con rivestimento di carbonio biocompatibile
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5163958A (en) 1989-02-02 1992-11-17 Cordis Corporation Carbon coated tubular endoprosthesis
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5236457A (en) 1992-02-27 1993-08-17 Zimmer, Inc. Method of making an implant having a metallic porous surface
US6613749B1 (en) 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0965336A1 (en) 1995-11-09 1999-12-22 Microbiological Research Authority Microencapsulated DNA for gene therapy
US20020001574A1 (en) 1995-12-13 2002-01-03 Jon A. Woiff Process of delivering a polynucleotide to a muscle cell via the vascular system
US5843172A (en) 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DE19855421C2 (de) 1998-11-02 2001-09-20 Alcove Surfaces Gmbh Implantat
CA2425665C (en) 2000-10-31 2013-07-16 Cook Incorporated Coated implantable medical device
US7803149B2 (en) 2002-07-12 2010-09-28 Cook Incorporated Coated medical device
CN1725988A (zh) 2002-11-13 2006-01-25 斯特根有限公司 具有多孔层的医用装置及其制造方法
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
AU2004294824A1 (en) * 2003-12-03 2005-06-16 Coda Therapeutics (Nz) Ltd Antisense compounds targeted to connexins and methods of use thereof
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
US20180099029A9 (en) 2010-04-15 2018-04-12 Mount Sinai School Of Medicine Serca2 therapeutic compositions and methods of use
DK2638163T3 (en) * 2010-11-12 2017-07-24 Massachusetts Gen Hospital POLYCOMB-ASSOCIATED NON-CODING RNAs
EP2655621B1 (en) * 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
FI3597749T3 (fi) 2012-05-25 2023-10-09 Univ California Menetelmiä ja koostumuksia rna-ohjattua kohde-dna-modifikaatiota varten ja rna-ohjattua transkription modulaatiota varten
EP2877213B1 (en) 2012-07-25 2020-12-02 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
EP2880171B1 (en) 2012-08-03 2018-10-03 The Regents of The University of California Methods and compositions for controlling gene expression by rna processing
KR101656236B1 (ko) 2012-10-23 2016-09-12 주식회사 툴젠 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
PT3363902T (pt) 2012-12-06 2019-12-19 Sigma Aldrich Co Llc Modificação e regulação de genoma baseadas em crispr
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
EP4234696A3 (en) 2012-12-12 2023-09-06 The Broad Institute Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
ES2576126T3 (es) 2012-12-12 2016-07-05 The Broad Institute, Inc. Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
KR20150105956A (ko) 2012-12-12 2015-09-18 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작 및 치료적 적용을 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
CA2951721C (en) * 2014-06-12 2023-09-26 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528678A (ja) * 2005-02-03 2008-07-31 コーダ セラピューティクス リミテッド 抗コネキシン化合物およびそれらの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEART, LUNG AND CIRCULATION, 2013, VOL.22, PP.557-558, ABSTRACT NO. 20, JPN6020028934, ISSN: 0004322027 *

Also Published As

Publication number Publication date
EP4043074A1 (en) 2022-08-17
WO2017027910A1 (en) 2017-02-23
AU2016309948A1 (en) 2018-03-08
AU2016309948B2 (en) 2021-05-20
CA3033909A1 (en) 2017-02-23
EP3334746A1 (en) 2018-06-20
AU2021215254A1 (en) 2021-09-02
EP3334746B1 (en) 2021-11-24
US20190030063A1 (en) 2019-01-31
EP3334746A4 (en) 2019-04-24
JP2021176848A (ja) 2021-11-11
JP7668686B2 (ja) 2025-04-25
US10709726B2 (en) 2020-07-14

Similar Documents

Publication Publication Date Title
Mearini et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice
Ivanchenko et al. Mini-PCDH15 gene therapy rescues hearing in a mouse model of Usher syndrome type 1F
CN110381982B (zh) 与myomixer促进的肌细胞融合相关的组合物和方法
KR20180008641A (ko) 심부 인트론 돌연변이의 유전자 편집
US11173215B2 (en) Method of gene transfer for the treatment of recessive catecholaminergic polymorphic ventricular tachycardia (CPVT)
KR101043433B1 (ko) 마이크로ｒｎａ분자를 포함하는 항암 조성물
TW202208402A (zh) Mybpc3多肽及其用途
US20230295654A1 (en) Methods and compositions for treatment of fragile x syndrome
CN116887868A (zh) 达农病的治疗
CN111686124B (zh) miR-486-3p在制备治疗SAH导致的神经炎症产品中的应用
JP7668686B2 (ja) 治療用コネキシン４５阻害剤
US20250049957A1 (en) Csf transport pathway for delivery of agents to inner ear
US20240408239A1 (en) Compositions and methods to prevent, inhibit or treat neurodegenerative diseases
US10214741B2 (en) Methods and compositions for inhibiting retinopathy of prematurity
EP4453220A1 (en) Compositions and methods for delivery of agents to inner ear
CN111349701B (zh) Rsph14基因用途、rsph14抑制剂用途、核酸分子、构建体及组合物
JP2023521383A (ja) Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物
CN118697878B (zh) Cd36作为抑制肺癌脑膜转移的分子标志物和治疗靶点的应用
Wei et al. A Novel AAV Capsid-Mediated RS1 Gene Therapy Restored Retinal Function to Wild-Type Levels in Rs1R213W Mouse Model
CN120860261A (zh) Angulin-1基因和/或Angulin-1蛋白在制备抗衰老及治疗衰老相关疾病的产品中的应用
WO2025030125A1 (en) Applications of cmya5 minigenes
WO2024097602A2 (en) Gene therapy for lemd2 cardiomyopathy
CN120718885A (zh) 一种用于治疗青光眼的gRNA、AAV表达载体、CRISPR-CasRx系统
KR20110039527A (ko) 마이크로 ｒｎａ분자를 포함하는 항암 조성물

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200811

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210624

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210624

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210702

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210706

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210806

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210817

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220614

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230608